AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00738387
Drug: ASA404
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1800 mg/m2 of ASA404 i.v. on day 1 of each 21 day cycle
Trial: NCT01057511
Drug: Crinone 8%
RxNorm normalized name: Crinone 8% Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crinone 8%, 90mg / p.v. / Qd, 7 days totally.
Trial: NCT02070965
Drug: Comp01 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02744872
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00054457
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02515331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule - oral dose
Trial: NCT02902523
Drug: Viread® tablet 300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administration(PO) in the fasted state
Trial: NCT02902523
Drug: HUG116 tablet 245mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administration(PO) in the fasted state
Trial: NCT00567008
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo BID for 8 weeks
Trial: NCT03305848
Drug: Nitrostat 0.4Mg Sublingual Tablet
RxNorm normalized name: Nitrostat 0.4mg Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 3 administrations of 0.4mg sublingual nitroglycerin tablets, dissolved in 10mL tap water, given orally in a single swallow. Each administration is separated by at least 5 minutes, and only if systolic blood pressure \> 100 mmHg.
Trial: NCT02939794
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (normal saline, sodium chloride)
Trial: NCT03452943
Drug: TEV-50717
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6, 9, 12, 15, and 18 mg oral tablets
Trial: NCT03452943
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to TEV-50717 tablets will be taken BID for 12 weeks.
Trial: NCT03910985
Drug: Duovent HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bronchodilation
Trial: NCT00302289
Drug: tyrosine, green tea, caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02688738
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02252354
Drug: [14C]-TAK-385 Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-385 oral radiolabelled solution
Trial: NCT02252354
Drug: [14C]-TAK-385 Solution for Intravenous Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-385 intravenous (IV) radiolabelled solution
Trial: NCT04470063
Drug: DDO-3055 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-dose for DDO-3055 tablets
Trial: NCT04470063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-dose for Placebo
Trial: NCT04594681
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered once daily or three times daily.
Trial: NCT04594681
Drug: KHK4951
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KHK4951 is administered once daily or three times daily.
Trial: NCT01330303
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SECOTEX® (tamsulosin hydrochloride) 0,4 mg (Boehringer Ingelheim)
Trial: NCT01330303
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tamsulosin hydrochloride 0,4 mg (Synthon BV)
Trial: NCT00857571
Drug: 150 mg Tablet
RxNorm normalized name: Ogsiveo 150 MG Tablet 7-Day 14 Count Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 150 mg of PF-02413873 tablets
Trial: NCT00857571
Drug: 30 mg Tablet
RxNorm normalized name: Triumeq PD 60 MG / 5 MG / 30 MG Tablet for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 30 mg of PF-02413873 tablets
Trial: NCT00857571
Drug: 400 mg Tablet
RxNorm normalized name: Aciclovir 400 mg tablet for oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 400 mg of PF-02413873 tablets
Trial: NCT00857571
Drug: 5 mg Tablet
RxNorm normalized name: Meloxicam 7.5 mg TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 5 mg of PF-02413873 tablets
Trial: NCT00857571
Drug: 750 mg Tablet
RxNorm normalized name: Spritam 750 MG Tablet for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 750 mg of PF-02413873 tablets
Trial: NCT00613171
Drug: STI571
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STI571 tablets taken orally once a day
Trial: NCT00564512
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
Trial: NCT01026246
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo used will be normal saline (0.9 percent NaCl).
Trial: NCT00481117
Drug: LY2405319
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00481117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04563936
Drug: LY01005 3.6 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
Trial: NCT04563936
Drug: ZOLADEX® 3.6 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
Trial: NCT00138008
Drug: endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: endocrine therapy
Trial: NCT00491868
Drug: R744 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 μg/4week for 24 weeks
Trial: NCT00491868
Drug: rHuEPO placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 IU 2 or 3 times/week for 8 weeks, then 1\~3 times/week for 16 weeks
Trial: NCT04991207
Drug: BIA 5-1058
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral BIA 5-1058 (Zamicastat) 100 mg tablets
Trial: NCT00150280
Drug: celecoxib and ibuprofen SR
RxNorm normalized name: amlodipine and celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04359147
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Effects on neural correlates of decision-making under risk and selective attention to threat
Trial: NCT04359147
Drug: Yohimbine + Hydrocortisone
RxNorm normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effects on neural correlates of decision-making under risk and selective attention to threat
Trial: NCT04359147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effects on neural correlates of decision-making under risk and selective attention to threat
Trial: NCT01112059
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg twice a day for 8 days
Trial: NCT00091611
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01922505
Drug: PPI triple therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03759392
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo twice daily for up to 20 weeks
Trial: NCT03573622
Drug: Anpl-one SR Tab. 300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
Trial: NCT03573622
Drug: Sarpodipil SR Tab. 300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
Trial: NCT02456740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection once a month
Trial: NCT01243957
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine: 60 mg po QD for 7 days (Days 4-10) then 20 mg po QD for 17 days (Days 11-27)
Trial: NCT03817190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule
Trial: NCT03689465
Drug: CTX
RxNorm normalized name: CTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In PTCy-ATG group, CTX will be intravenously infused via a central venous catheter on day +4 at a dose of 50mg/kg/d.
Trial: NCT04208152
Drug: anle138b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule containing excipient and anle138b
Trial: NCT01937871
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00970593
Drug: placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 \& 2: PBO x 7 days BID Group 3: PBO QD x 14 days Group 4: PBO QD x 14 days Group 5: PBO QD x 14 days Group 6: PBO QD x 14 days
Trial: NCT03719625
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparaison of Norepinephrin and Ephedrin for prevention of the post spinal anesthesia in cesarean section
Trial: NCT04647903
Drug: ADAIR 10 mg IR tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: manipulated ADAIR 3x10mg
Trial: NCT04647903
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for oral and intranasal administration
Trial: NCT02807337
Drug: Caphosol
RxNorm normalized name: Caphosol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02807337
Drug: 0,9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00696215
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 mg once a day
Trial: NCT04468685
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interperitoneal administration in the gall bladder bed
Trial: NCT00648778
Drug: Loxitane® Capsules 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg, single dose fasting
Trial: NCT01722578
Drug: L-ornithine L-aspartate
RxNorm normalized name: L-ornithine L-aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ornithine L-aspartate (6 ampules, each ampule containing 5 grams of the drug in 10 ml solution) to be diluted in 440 ml of Dextrose 5% (to make a total of 500 ml of solution), as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
Trial: NCT01722578
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sterile water, 60 ml) diluted in 440 ml of Dextrose 5%, as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
Trial: NCT02531529
Drug: dexmedetomedine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intraoperative infusion
Trial: NCT02531529
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03252067
Drug: azithromycin eyedrop
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tear samples will be collected using the strips.
Trial: NCT02288312
Drug: BIA 2-093
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02411825
Drug: SAR425899
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Trial: NCT02411825
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Trial: NCT00714116
Drug: SBI-087
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV or SC dose of SBI-087
Trial: NCT01863914
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arteriovenous fistula surgery was performed after 1-week treatment with placebo or Rosuvastatin (randomized, double blind). The intervention drug treatment continues for 3 more weeks after creation of AV fistula.
Trial: NCT01951924
Drug: Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03399513
Drug: R-CHOEP chemotherapy
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunochemotherapy
Trial: NCT04584684
Drug: 0.12% Chlorohexidine Gluconate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentist prescribed antimicrobial mouth rinse
Trial: NCT04584684
Drug: 27% Ethanol plus essential oils
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Over-the-counter antiseptic mouth rinse
Trial: NCT02726659
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunct celecoxib
Trial: NCT02726659
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunct placebo
Trial: NCT04629378
Drug: Rifafour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifafour (HRZE) Standard dose
Trial: NCT00545714
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 250 mg/m\^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
Trial: NCT00995124
Drug: NeutraLice Lotion
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Head lice topical application to be applied once for 10 minutes.
Trial: NCT00995124
Drug: NeutraLice Advance Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: head lice application to be applied once for 10 minutes
Trial: NCT00995124
Drug: Moov Head Lice Solution
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single application for head lice with 10 min application time.
Trial: NCT03997812
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of 0 mg of VVZ-149
Trial: NCT03889886
Drug: SDP-4 Ophthalmic Solution (0.1%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
Trial: NCT03889886
Drug: SDP-4 Ophthalmic Solution (1.0%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
Trial: NCT03889886
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
Trial: NCT00631592
Drug: GSK1349572
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01639157
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be maintained on oral placebo (0 mg administered 3 times daily) for 6 days each during the study in random order.
Trial: NCT00367653
Drug: Azithromycin plus Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azithromycin 1000 mg by mouth (PO) (two 500 mg tablets) once daily (QD) for 3 days(Days 0, 1, 2) plus chloroquine 600 mg base PO once daily for 3 days (Days 0, 1, 2)
Trial: NCT00978016
Drug: Placebo-Cohort 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (placebo) for 7 weeks including titration and taper periods
Trial: NCT00978016
Drug: PPI
RxNorm normalized name: PPIase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD
Trial: NCT02958696
Drug: HTL0018318
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two single doses of active drug (low, mid or high dose either as aqueous solution or capsule) separated by a washout of at least 12 days.
Trial: NCT02111096
Drug: LY2409021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02111096
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02111096
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02127749
Drug: Endotoxin
RxNorm normalized name: Endotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups will receive 2 ng/kg LPS (endotoxin) intravenously
Trial: NCT05024825
Drug: hydrocodone, acetaminophen and ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the hydrocodone group will receive scheduled doses of hydrocodone, acetaminophen and ibuprofen at scheduled doses. Acetaminophen 15mg/kg (max 1 gm) every 4-6 hours as needed for pain, max dose 4 gm per day; Ibuprofen 4-10 mg/kg PO divided over 8 hours as needed for pain, max dose 40 mg/kg/day; hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain.
Trial: NCT00006286
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03788343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules are indistinguishable in their appearance from Phe capsules
Trial: NCT03168022
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x TNX-102 SL 2.8 mg yellow tablet (commercial manufacturer) to be held under the tongue until dissolved.
Trial: NCT03168022
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x TNX-102 SL 2.8 mg white tablet (original manufacturer) to be held under the tongue until dissolved.
Trial: NCT02187536
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04334317
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-071 placebo-matching tablet.
Trial: NCT01290003
Drug: Piperacillin-Tazobactam and Amikacin
RxNorm normalized name: piperacillin / tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inj Piperacillin-Tazobactam 50 mg/Kg/dose 12 hourly IV X 3 days (6 doses) Inj Amikacin 15 mg/kg/dose 24 hourly IV X 3 days (3 doses)
Trial: NCT05485818
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12±4 hours after PCI: 0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
Trial: NCT05485818
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12±4 hours after PCI: 2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
Trial: NCT00188045
Drug: Propranolol - Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02969044
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03855982
Drug: Drug inducing myocarditis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs susceptible to induce myocarditis
Trial: NCT04650204
Drug: Anticonvulsant Agent
RxNorm normalized name: ANTICONVULSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given ASD
Trial: NCT01683396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for subcutaneous injection
Trial: NCT04968613
Drug: placebo monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In addition to basic treatment, the patient also received selegiline treatment
Trial: NCT00929851
Drug: CHF1535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose
Trial: NCT03106428
Drug: MEDI7247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study will enroll patients with R/R AML/MM/DLBCL who will receive MEDI7247 IV
Trial: NCT01047254
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03093259
Drug: ABX464
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABX464 is a new Anti-inflammatory drug
Trial: NCT03093259
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching with ABX464
Trial: NCT04211831
Drug: URO-902
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intradetrusor injection
Trial: NCT04211831
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intradetrusor injection
Trial: NCT00317629
Drug: controlled nitric oxide releasing patch
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily nitric oxide patch application during 20 days